In March of 2024, Trisha Johnson was diagnosed with invasive ductal carcinoma breast cancer. While this form of cancer is highly treatable, the surgeries and treatment were far more invasive than originally planned. Trisha endured a lumpectomy to remove the tumors as well as several lymph nodes. Her medical team also advised that she receive radiation therapy. Prior to this treatment a medical device called Biozorb was implanted into her breast tissue. The Biozorb implant is used to ensure radiation is delivered to the tumor bed while minimizing exposure to normal tissue. This device was originally designed to reabsorb into the patient’s system. In February 2024 the Biozorb implant was recalled by the manufacturer due to severe complications in a number of patients. The implant was actually placed in her breast 8 weeks after the first recall. Sadly, the surgeon and the hospital claim that either knew of the initial recall. Unfortunately, Trisha’s body also rejected the implant. Complications started within days of the device placement. The first being a large hematoma consisting of more than 24 ounces of fluid. This is the equivalent of 2 cans of soda. The Biozorb device was eventually removed after completion of the radiation therapy. Since then Trisha has had 3 additional procedures to remove seromas or pockets of fluid in the breast tissue. Finally, on October 25, 2024 the Biozorb device was recalled as a class 1 by the FDA citing serious adverse events including death.

Thankfully, Trisha is now in remission. She is still recovering from the numerous surgeries and procedures. The overall prognosis is positive. Reconstruction of the tissue is highly likely. Unfortunately, Trisha has been unable to work for the majority of 2024 including several weeks in 2025. This has caused unexpected, severe financial hardship. As her friends and family, we kindly thank you for any of your contributions.